New players on the patent chess board

The advent of inter partes review (IPR) proceedings under the America Invents Act (AIA) has introduced new players to the traditional patent litigation scene in the US. Among others, new entrants range from not-for-profits, with ideological motivations, to for-profit entities leveraging IPRs for financial gain.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.

Americas

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

Americas

LSD trade secrets suit over clinical trail info thrown out by judge

2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.

More features

Sanofi launches mRNA lawsuits on Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

BioNTech and Pfizer secure big European win over mRNA patent

Influential Women in IP 2026: Who made the list?

WilmerHale trade secrets expert moves to new firm

New players on the patent chess board

More on this story

Editor's picks

Editor's picks

More features